MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • 2024 International Congress
    • 2023 International Congress
    • 2022 International Congress
    • MDS Virtual Congress 2021
    • MDS Virtual Congress 2020
    • 2019 International Congress
    • 2018 International Congress
    • 2017 International Congress
    • 2016 International Congress
  • Keyword Index
  • Resources
  • Advanced Search

Amantadine Is Effective Long-term in Parkinson’s Disease

S. Park, BS. Jeon (Daejeon, Republic of Korea)

Meeting: 2022 International Congress

Abstract Number: 755

Keywords: Amantadine, Parkinson’s

Category: Parkinson’s Disease: Clinical Trials

Objective: This study aimed to investigate the long-term effectiveness of amantadine in patients with PD.

Background: Amantadine has been used in the symptomatic treatment of Parkinson’s disease (PD), buy it is only known to be effective in the early months except in some studies.

Method: Of the 54 drug naïve patients who were started on amantadine for a 3-year study to examine whether amantadine prevents development of dyskinesia, 30 patients who were still on amantadine after a mean follow up of 8 years were enrolled in this study. At baseline, Unified Parkinson’s Disease Rating Scale (UPDRS), Freezing of Gait Questionnaire (FOGQ), Non-motor Symptom Scale (NMSS), and Parkinson’s Disease Questionnaire 39 (PDQ39) were assessed. Then, the participants were asked to discontinue amantadine. Clinical evaluations were repeated at 4- and 8-week follow-ups.

Results: Twenty-four patients presented with various motor and non-motor symptoms after amantadine discontinuation, which improved reintroduction of amantadine. However, 6 patients reported no worsening after discontinuing amantadine for up to eight weeks.

Conclusion: Twenty-four patients presented with various motor and non-motor symptoms after amantadine discontinuation, which improved reintroduction of amantadine. However, 6 patients reported no worsening after discontinuing amantadine for up to eight weeks.

To cite this abstract in AMA style:

S. Park, BS. Jeon. Amantadine Is Effective Long-term in Parkinson’s Disease [abstract]. Mov Disord. 2022; 37 (suppl 2). https://www.mdsabstracts.org/abstract/amantadine-is-effective-long-term-in-parkinsons-disease/. Accessed June 15, 2025.
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2022 International Congress

MDS Abstracts - https://www.mdsabstracts.org/abstract/amantadine-is-effective-long-term-in-parkinsons-disease/

Most Viewed Abstracts

  • This Week
  • This Month
  • All Time
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Life expectancy with and without Parkinson’s disease in the general population
  • What is the appropriate sleep position for Parkinson's disease patients with orthostatic hypotension in the morning?
  • Patients with Essential Tremor Live Longer than their Relatives
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • What is the appropriate sleep position for Parkinson's disease patients with orthostatic hypotension in the morning?
  • Life expectancy with and without Parkinson’s disease in the general population
  • The hardest symptoms that bother patients with Parkinson's disease
  • An Apparent Cluster of Parkinson's Disease (PD) in a Golf Community
  • Effect of marijuana on Essential Tremor: A case report
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Estimation of the 2020 Global Population of Parkinson’s Disease (PD)
  • Patients with Essential Tremor Live Longer than their Relatives
  • Help & Support
  • About Us
  • Cookies & Privacy
  • Wiley Job Network
  • Terms & Conditions
  • Advertisers & Agents
Copyright © 2025 International Parkinson and Movement Disorder Society. All Rights Reserved.
Wiley